E
DURECT Corporation DRRX
$1.91 $1.36245.58% NASDAQ
Recommendation
Prev Close
$0.5527
Volume
45,108,602
Avg Vol (90D)
92,731
Market Cap
$17.16M
Dividend & Yield
--
52-Week Range
$0.4801 - $1.69
P/E (TTM)
6.10
EPS (TTM)
$0.0906
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Durect (DRRX) Downgraded Following Acquisition Agreement
7/29/2025 - GuruFocus
Durect just downgraded at Northland, here's why
7/29/2025 - The Fly
DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is ...
7/29/2025 - GuruFocus
Why Is Durect Stock (DRRX) Up 270% Today?
7/29/2025 - TipRanks Financial Blog
DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders
7/29/2025 - Business Wire
Durect (DRRX) Shares Soar 258% on Bausch Health Acquisition Deal
7/29/2025 - GuruFocus
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative ...
7/29/2025 - GuruFocus
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative ...
7/29/2025 - GuruFocus
Bausch Health to Acquire DURECT Corporation: A Strategic Move in Hepatology BHC stock news
7/29/2025 - GuruFocus
Bausch Health to acquire liver drug developer Durect for $1.75 per share
7/29/2025 - Seeking Alpha - Healthcare
Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price for Its Public Shareholders
7/29/2025 - Business Wire
BHC to Acquire DURECT Corporation in $63M Deal with Future Milestones
7/29/2025 - GuruFocus
Durect Merges with Bausch Health for $1.75/Share
7/29/2025 - TipRanks Financial Blog
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative ...
7/29/2025 - GuruFocus
BHC to Acquire DURECT in $63 Million Deal with Potential Future Milestones
7/29/2025 - GuruFocus
Bausch Health to acquire Durect for $1.75 per share in cash upfront
7/29/2025 - TipRanks Financial Blog
Bausch Health to acquire Durect for $1.75 per share in cash upfront
7/29/2025 - The Fly
Bausch Health to acquire Durect for $1.75 per share in an all-cash transaction
7/29/2025 - The Fly
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
7/29/2025 - ACCESS Newswire
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
7/29/2025 - PR Newswire
bausch health bags phase 3 ready liver prospect 63m durect buyout
7/29/2025 - FierceBiotech.com - Biotech
Durect Receives Nasdaq Delisting Notice Extension
7/11/2025 - TipRanks Financial Blog
Analysts Offer Insights on Healthcare Companies: I-MAB (IMAB) and Durect (DRRX)
5/17/2025 - TipRanks Financial Blog
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update ...
5/13/2025 - GuruFocus
DURECT (DRRX) Q1 Revenue Surpasses Estimates, Focuses on Phase 3 Trial Funding DRRX Stock News
5/13/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$4.87M
EBITDA (TTM)
-$14.79M
EBIT (TTM)
-$14.93M
Net Income (TTM)
-$4.46M
Balance Sheet
Total Assets (Q)
$14.36M
Total Debt (Q)
$1.98M
Total Liabilities (Q)
$9.01M
Book Value Per Share (Q)
$0.1724
Cash Flow
Cash from Operations (TTM)
-$10.35M
Cash from Investing (TTM)
$1.42M
Cash from Financing (TTM)
-$4.28M
Net Change in Cash (TTM)
-$13.21M
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
0.02
7-Day Total Return
257.71%
30-Day Total Return
211.35%
60-Day Total Return
230.14%
90-Day Total Return
139.35%
Year to Date Total Return
142.13%
1-Year Total Return
16.40%
2-Year Total Return
-44.18%
3-Year Total Return
-60.92%
5-Year Total Return
-90.28%
52-week Low
May 28, 2025 - $0.4801
52-week High
Jul 29, 2024 - $1.69
Valuation
Market Cap
$17.16M - Nano Cap
Enterprise Value
$10.88M
Price/Sales (TTM)
3.52
Price/Book (Q)
3.21
Dividends and Shares
Shares Outstanding
31.04
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.durect.com
Phone Number
408 777 1417
Address
10240 Bubb Road
Cupertino, CA 95014-4166
Country
United States
Year Founded
1998
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product candidate includes larsucosterol, an endogenous, orally... more
NASDAQ 07/29/2025 12:49PM Eastern Quotes delayed